Pixclara® (18F-FET) Is Generally Well Tolerated1
Actor portrayals
No serious adverse events were reported in either study that evaluated the safety of Pixclara®
Clinical trials experience
The safety of Pixclara® is based on the analyses of 382 patients from 2 clinical trials who received at least 1 dose of Pixclara®.a
Adverse reactions that occurred in <0.5% of patients were:
Nausea
Injection site reaction
Fatigue and malaise
- Headache occurred in 0.5% of patients
Pediatric patients
The safety profile observed in pediatric patients (1 month of age and older) was consistent with the safety profile in adult patients.
Learn how Pixclara® is dosed and administered.
View InformationaBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.